Daily Stock List
MIMVI, Inc. (MIMV)
Greenbackers and Wall Street Resources reported this week on MIMVI, Inc. (MIMV), Stock Alerts, Penny Stock Bets, The Stock Psycho, Top Gun, PennyTrader Publisher, Information Solutions Group did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
MIMVI, Inc. is a pure-play search and recommendation technology company. They focus on developing algorithms and technology for personalized search, recommendation, and discovery services to the consumer and enterprise. The Company's personalization technology automates the organization of content. MIMVI lists on the OTCQB; the Company has their corporate headquarters in Sunnyvale, California.
MIMVI's proprietary search and "intelligent" recommendation algorithms enable the search and discovery of Mobile Apps, Mobile Content and Mobile Products across multiple devices and platforms. These include Apple's iPhone and iPad, Google Android, BlackBerry, Windows Phone, Facebook and Web Apps. The basis of MIMVI's technology is on proprietary search, recommendation and personalization algorithms. It was released in July 2010.
The Company offers MIMVI ECHO™. The MIMVI ECHO program helps mobile app companies drive more downloads by way of their pre-built social audience using creative, non-invasive messaging to millions of end users who use their mobile devices as a primary tool to engage. Multiple patents are in process for MIMVI ECHO™. Based on a newly formed partnership with Microsoft, Mimvi will be working closely with the Microsoft Azure team to advance MIMVI ECHO™ algorithms and apps initially with deployments across Windows Azure, Microsoft's Cloud Platform. MIMVI ECHO™ combines the Company's best-in-class proprietary search and recommendation technology with a pre-built social community consisting of tens of millions of active mobile users.
The Company also has their MIMVI Link™ offering. MIMVI Link™ is a unique and proprietary technology that matches mobile apps to web content. MIMVI Link™ represents a new kind of advertising service, connecting mobile app publishers to web content publishers.
Recently, MIMVI announced that technology industry veteran and enterprise relationship specialist, Mr. Dan Acquafredda, joined the Company's Advisory Board. Mr. Acquafredda provides MIMVI over two decades of executive experience in the telepresence and telecom space. He is currently Vice President of Business Development at Fuzebox, Inc., a worldwide leader in real-time visual collaboration applications.
MIMVI, Inc. (MIMV), closed Friday's trading session at $0.0352, up 2.03%, on 62,920 volume with 30 trades. The average volume for the last 60 days is 546,426 and the stock's 52-week low/high is $0.04/$0.717.
Pristine Solutions, Inc. (PRTN)
OTCtipReporter, PennyStockScholar, SmallCapInvestorDaily, Penny Stocks Expert, The Stock Psycho, and Top Gun reported recently on Pristine Solutions, Inc. (PRTN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Pristine Solutions, Inc., by way of their wholly owned subsidiary company, Eaton Scientific Systems, Inc., holds the intellectual property and global marketing rights to Tropine 3 (a novel indication of Homatropine). This is a patent pending novel indication of this existing Food & Drug Administration (FDA) approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women. Eaton Scientific Systems established in January 2006 in Los Angeles, California; Eaton has their headquarters in Beverly Hills, California. Pristine Solutions shares trade on the OTC Markets – OTCQB.
The Company's Eaton Scientific Systems has a mandate to develop, license and seek U.S. and International regulatory approvals of their drugs and treatments targeting women's health. Their Tropine 3 is an orally ingested prescription product containing Homatropine that is intended to reduce climacteric symptoms and improve quality of life in menopausal women not receiving HRT (women who are experiencing "hot flashes" and "night sweats"). So far, doctors in Los Angeles have prescribed a compound version of Tropine 3 to their patients who are experiencing hot flashes.
Recent scientific research has indicated that women in the U.S. and Europe reach menopause at a median age ranging from 50.1 to 51.4 years. This same research study concluded that in Latin America the median age of menopause was 43.8 to 53 years, and in Asia from 42.1 to 49.5 years. Other large research studies also concluded that the frequency of menopause symptoms range from 36–50 percent of women in North America, up to 45–69 percent in Latin America, 22–63 percent in Asia, and 74 percent in Europe.
Eaton Scientific Systems believes that the earlier onset of menopause and the increased prevalence of menopause symptoms outside of North America represent a vital strategic opportunity to expand Tropine 3 awareness on a worldwide scale. They could potentially enter into business arrangements with established drug distribution organizations to accomplish this.
Eaton Scientific Systems has retained a team of accredited medical professionals. The Company has completed their Clinical Trial Protocol as of September 28, 2012 and the Company expects to submit their Protocol to the Institutional Review Board (IRB). The Company is looking to obtain FDA approval to begin a Clinical Trial.
The purpose of the clinical trial will be to obtain the regulatory approval of Tropine 3 by the FDA. The Clinical Trial will be a Phase 2-3, Prospective, Randomized, Double Blind, Placebo-Controlled, Dose Escalation, Parallel-Group-Study. The Company anticipates that the Study will be completed, excluding any unforeseen delays, some time during the 2nd calendar quarter of 2013.
Pristine Solutions, Inc. (PRTN), closed Friday's trading session at $0.0046, down 4.17%, on 5,990,619 volume with 100 trades. The average volume for the last 60 days is 14,521,506 and the stock's 52-week low/high is $0.004/$0.53.
RTG Ventures, Inc. (RTGV)
Greenbackers reported recently on RTG Ventures, Inc. (RTGV), PennyTrader, Orbit Stocks, HotShotStocks did earlier, and we highlight the Company today, here at the QualityStocks Daily Newsletter.
Trading on the OTCQB, RTG Ventures, Inc. offers Music and Entertainment Technology Solutions and Digital Marketing Services. The Company, harnessing the strength of their digital marketing agency, has applied their knowledge process in developing innovative technology platforms for web, mobile, as well as tablet devices. RTG Ventures has their corporate headquarters in Washington, DC.
The Company's vision is to make live music available anywhere, any time and in any format. The design of this is to keep fans connected with their artists at their convenience but always in a way that respects the artists' need to feed their creativity. RTG Ventures serves the technology, media, online advertising & marketing, streaming music and social media & entertainment industries.
RTG Ventures provides solutions and execution within the online marketing sector; Strategy & Consulting within advertising and media, and Revenue Model planning & consultancy for companies taking a product/service online. They also provide Music & Entertainment Technology Solutions; Search Marketing, including PPC (Google AdWords, Microsoft adCenter) & SEO (Organic Search); Social Media strategy planning and execution; Analytics, and Web Design & Development services for Web, tablet and mobile devices.
The Company has two Music platforms - audigist360 and Pulse Station. Audigist is a beta music hosting service that allows artists and bands to sell their music direct to their fans. Pulse Station is a unique social music management platform that allows artists and their management and label to 'house' all the artists audio, music and video in one easy to manage environment.
As pertains to Digital Marketing Services, Digital Clarity is the trading brand of Stylar Ltd., a wholly owned subsidiary of RTG Ventures. Utilizing Digital Clarity's application in the Marketing and Social arena, RTG Ventures offers intelligent, and analytics based technology solutions with the support of an experienced digital marketing team.
In June of this year, RTG Ventures formed a business combination with Brand Entertain. This company is a Santa Barbara, California private company. They play the roles of developer, packager, co-producer and licensor when it comes to original branded entertainment and media platforms. Brand Entertain develops strategic, multi-channel branded entertainment properties and ventures that drive consumer engagement and grow product sales for brand partners online and in-store.
RTG Ventures, Inc. (RTGV), closed Friday's trading session at $0.0006, up 100.00%, on 36,412,019 volume with 26 trades. The average volume for the last 60 days is 6,525,643 and the stock's 52-week low/high is $0.0002/$0.0049.
MacroSolve, Inc. (MCVE)
PennyStockNewsletter.info, Corporate Profile Media, The Momentum Traders Network, Premium Stock Picks, Stock Exploder, Day Trade Alert, StockGuru, and FeedBlitz reported earlier on MacroSolve, Inc. (MCVE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
MacroSolve, Inc. is a company with a robust intellectual property (IP) portfolio. They are advancing throughout the mobile applications era by innovating key technologies that have laid the foundation for apps and next-generation developers. Founded in 1997, MacroSolve lists on the OTCQB. The Company has their headquarters in Tulsa, Oklahoma.
MacroSolve is a leading developer and marketer of mobile technologies. They leverage their IP portfolio, including their recently issued landmark patent, and generate revenues through licensing and consulting. The Company has a history of landmark achievements ranging from patent #7,822,816, to the creation and recent sale of the Illume Mobile division, the formation and sale of the DigiTicket division, as well as other product ventures.
MacroSolve's business strategy, with the sale of the Illume division, is focusing on taking advantage of their IP strength and corporate experience, specifically through undertaking new ventures with growth-oriented target companies seeking market intelligence and mentorship.
Concerning Revenue Streams, at present, the expectation is that patent license royalties and settlements from enforcement actions will continue throughout the life of the '816' patent, which expires in 2025. Additional patent licensing revenues will come from DecisionPoint as they continue growing Illume Mobile across the country.
MacroSolve believes that commission revenues and other success fees may come from DecisionPoint by MacroSolve's sourcing new customers and synergistic businesses. MacroSolve's strategy also includes future license revenues and consulting fees generated by executing the new strategy with targeted mobile app companies.
This past September, MacroSolve announced their issuance of a Letter to Shareholders. The letter provides updates on significant developments at the Company including an advantageous sale of the Illume Mobile business unit to Decision Point Systems, Inc., and a significant reduction of MacroSolve overhead. The letter also highlights developments such as cash flow positive expectations in the third quarter of 2012, and profitability in the fourth quarter of 2012. The letter also highlights the launch of a new strategy that the Company believes will result in favorable returns for shareholders, and the offering of intellectual property and corporate experience in new ventures.
MacroSolve, Inc. (MCVE), closed Friday's trading session at $0.04, even for the day, on 5,400 volume with 2 trades. The average volume for the last 60 days is 111,866 and the stock's 52-week low/high is $0.02/$0.135.
Nile Therapeutics, Inc. (NLTX)
PennyInvest, StockEgg, StockRich, BullRally, HotOTC, PennyStockVille, MadPennyStocks, CoolPennyStocks, Wise Alerts, PennyTrader Publisher, Momentum Traders, Daily Markets, and The Penny Play reported earlier on Nile Therapeutics, Inc. (NLTX), and we highlight the Company today, here at the QualityStocks Daily Newsletter.
Founded in 2005, Nile Therapeutics, Inc. is a clinical stage biopharmaceutical company that lists on the OTC Markets: OTCQB. The Company is developing innovative products for the treatment of cardiovascular disease, with their initial focus on heart failure. Their lead product candidate includes Cenderitide, and they develop CU-NP as well. Nile Therapeutics has their corporate headquarters in San Mateo, California.
Their lead product Cenderitide is undergoing development to treat patients following admission for acutely decompensated heart failure (ADHF). This is an acute exacerbation of heart failure. Nile Therapeutics believes that the continuous and extended infusion of cenderitide via a subcutaneous pump will provide patients with sustained symptomatic relief in the outpatient setting. The Company believes this could contribute to a reduction in post-acute hospitalizations and persistent improvement in cardio-renal functions.
Nile Therapeutics and Medtronic, Inc. entered into an agreement, in February 2011, to collaborate on the development of cenderitide. Nile completed a Phase 1 pharmacokinetic/pharmacodynamic (PK/PD) clinical trial in Q4 2011. The design of the trial was to understand the doses required to achieve pre-determined plasma levels of cenderitide when delivered by way of a subcutaneous infusion pump.
For this year, Nile is initiating a Phase 2 placebo-controlled, dose ranging clinical trial in patients who were recently admitted to the hospital for ADHF. The Phase 2 trial will enroll approximately 300 patients. It will evaluate the endpoints of cardiac remodeling, renal function, re-hospitalization and mortality in patients after 90 days of continuous cenderitide therapy through subcutaneous pump.
In addition, Nile is advancing CU-NP. This pre-clinical program is evaluating the opportunity for chronic dosing of CU-NP for the potential treatment of several cardiovascular and renal diseases. In vivo studies of CU-NP have shown it to increase natriuresis, diuresis, and glomerular filtration rate (GFR) in a dose dependent manner; decrease cardiac filling pressure, and inhibit the renin-angiotensin system without inducing significant hypotension.
Nile Therapeutics, Inc. (NLTX), closed Friday's trading session at $0.075, up 4.90%, on 25,455 volume with 5 trades. The average volume for the last 60 days is 32,321 and the stock's 52-week low/high is $0.07/$0.63.
Sono-Tek Corp. (SOTK)
Stock Guru reported previously on Sono-Tek Corp. (SOTK), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Based in Milton, New York, Sono-Tek Corp. is a global leader in ultrasonic atomizing nozzle systems for applying precise, thin film coatings. Founded in 1975 by Dr. Harvey L. Berger, Ph.D. (Inventor of the ultrasonic nozzle), the Company is a leading developer and manufacturer of liquid spray products based on their proprietary ultrasonic nozzle technology. Their patented technologies produce micron size uniform droplets, creating ultra thin layers onto any size or shape substrate. A green technology enterprise, Sono-Tek's shares trade on the OTC Markets: OTCQB.
The Company's environmentally friendly ultrasonic spray systems result in premier performance coatings, with significant reductions in overspray; savings in raw material, water and energy usage; improved process repeatability and transfer efficiency, greater uniformity, and reduced emissions.
Major industries utilizing Sono-Tek's ultrasonic nozzle systems include electronics - printed circuit board fluxing, medical nanocoatings such as implantable device coatings onto stents, catheters, balloons and pacemakers, and fuel cell PEMs, thin film solar cells, and phosphoric doping. Industries also include anti reflection coatings, CIGs, float glass coatings, pan release coatings for commercial baking, spray drying, carbon nanotube suspensions, and any other spray application requiring uniform deposition with minimal overspray.
In October, Sono-Tek announced sales of $2,391,000 for the three months ended August 31, 2012, in comparison to sales of $3,150,000 for the previous year period, a decrease of $759,000 or 24 percent. The Company stated that the lower overall sales figure is primarily due to uncertainty in Europe and China affecting sales in those regions, and is consistent with the experience of other reporting companies.
Sono-Tek reported net income of $59,735 for the three months ended August 31, 2012. This is in comparison to $437,526 for the prior year period, a decrease of $377,791. Their gross profit margin remained healthy at 49 percent for the three months ended August 31, 2012. The current period reduction in net income was because of the decrease in overall sales levels. This has led to cost reductions to maintain profitability while the slowdown persists.
Sono-Tek Corp. (SOTK), closed Friday's trading session at $0.66, up 1.54%, on 25,200 volume with 11 trades. The average volume for the last 60 days is 6,270 and the stock's 52-week low/high is $0.63/$1.38.
Yippy, Inc. (YIPI)
OTCPicks, PennyTrader Publisher, HyperSpeedStocks, Greenbackers, Beacon Equity Research, PennyStockPickReport, and WePickPennyStocks reported earlier on Yippy, Inc. (YIPI), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Yippy, Inc. provides secure, family friendly, online web destinations and services. These include search, browser, email, cloud applications and storage to family personal computers (PCs), schools, learning institutions, educational companies, school districts, universities, and libraries in North America. Yippy is a technology enterprise specializing in the development of search, data normalization, and aggregation through application service environments for consumer and enterprise markets.
Founded in 2006, the Company has their headquarters in Fort Myers, Florida. The Company was formerly known as Cinnabar Ventures, Inc. They changed their name to Yippy, Inc. in April of 2010. Yippy trades on the OTCQX U.S.
The Company's proprietary web-based product suites undergo deployment over cloud architecture and provide secure, redundant and maintained "Data as a Service" for businesses and education markets. Additionally, Yippy operates a number of online web properties and educational reference websites.
In essence, Yippy is a metasearch engine. Yippy queries multiple search engines and combines the results to be displayed as a group, or cloud, on one screen. They retrieve results from Ask, Open Directory, Gigablast, as well as others.
Last month, Yippy announced the appointment of Mr. Edward Noel as the Company's new Chief Executive Officer. Mr. Richard Granville, the Company's previous Chief Executive Officer, has been appointed as the Executive Chairman of the Company's Board of Directors. Prior to his appointment, Mr. Noel served as a Director on the Board. He will continue to serve in that capacity in addition to his duties as Chief Executive Officer.
Mr. Noel has more than 15 years of business experience working in the Internet industry. This includes relative expertise in the areas of strategy, business development, search product management, mergers and acquisitions, ad sales and marketing. He joins Yippy after serving as the Chief Revenue Officer of Alphabird, Inc. Before joining Alphabird, from February 1999 to November 2011, Mr. Noel served as Chief Revenue Officer/Chief Strategy Officer of Lycos, Inc.
Yippy, Inc. (YIPI), closed Friday's trading session at $0.433, up 8.25%, on 84,345 volume with 17 trades. The average volume for the last 60 days is 51,228 and the stock's 52-week low/high is $0.11/$2.34.
Dacha Strategic Metals, Inc. (DCHAF)
Streetwise Reports reported previously on Dacha Strategic Metals, Inc. (DCHAF), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Incorporated in 1996, Dacha Strategic Metals, Inc. invests in physical strategic minerals, certain of which are presently unavailable directly to investors. The Company has acquired a strategic inventory of these minerals with a primary initial focus on Rare Earth Elements (REEs). Dacha Strategic Metals' shares list on the OTCQX International. The Company is based in Toronto, Ontario.
Dacha's focus is to achieve investment gains through the long-term appreciation in the value of their physical holdings of strategic minerals, particularly REEs. Their intention is to add value by becoming an active market participant in strategic minerals. The Company is working to meet this investment objective by assembling a portfolio of strategic minerals that they believe has the greatest potential for capital appreciation and subsequently employing a "buy-and-hold" investment strategy.
In addition, Dacha is working to meet this investment objective by opportunistically trading occasionally to realize gains to meet their objective. Their intention is that the majority of the funds they raise from time to time will be invested by the Operator to purchase and store inventories of Strategic Minerals in warehouses around the world that have approval by the London Metals Exchange or the Minor Metals Trade Association. Most of the Strategic Minerals purchased by the Operator are held, following delivery, at licensed warehouse facilities outside of China.
Dacha is initially focusing on stockpiling certain heavy rare earths: Terbium (Tb), Dysprosium (Dy), Gadolinium (Gd), Europium (Eu) and Yttrium (Y). On their list of critical strategic metals are Indium (In), Gallium (Ga), Selenium (Se), Tellurium (Te), Rhenium (Re) and Hafnium (Hf). Dacha Strategic Metals continually refines their definition of critical as the markets change.
Today, Dacha Strategic Metals sent a letter and mailed their Management Information Circular to all shareholders urging them to vote for their board nominees at the annual and special meeting of shareholders to take place on November 28, 2012. All shareholders of record as of October 15, 2012 are entitled to vote at the annual meeting, regardless of the number of shares held. Dacha warns against a stealth takeover attempt by dissidents. In addition, the Company nominated Mr. Jim Rogers among other skilled and experienced executives. Mr. Rogers is a commodities investment expert, author and a financial commentator who has been a successful international investor since 1980.
Dacha Strategic Metals, Inc. (DCHAF), closed Friday's trading session at $0.4683, up 3.15%, on 2,000 volume with 1 trade. The average volume for the last 60 days is 50,952 and the stock's 52-week low/high is $0.3274/$0.63.
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $5.35, up 10.54%, on 28,786 volume with 46 trades. The stock’s average daily volume over the past 60 days is 42,140 and its 52-week low/high is $0.72/$10.01.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer
TNI BioTech Signs Agreement With Government of Malawi to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.199, up 1.27%, on 68,914 volume with 83 trades. The stock’s average daily volume over the past 60 days is 68,914, and its 52-week low/high is $0.1771/$0.47.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
FDA Considering Faster Approval Process for Developers of Drugs for Deadly or Debilitating Diseases
Cardium Announces the Acquisition of To Go Brands
Cardium To Present At 2012 Noble Financial Life Sciences Investor Conference
Loans4Less.com, Inc. (LFLS)
The QualityStocks Daily Newsletter would like to spotlight Loans4Less.com, Inc. (LFLS). Today, Loans4Less.com, Inc. closed trading at $0.09, even for the day. The stock’s average daily volume over the past 60 days is 8,824, and its 52-week low/high is $0.01/$0.51.
Loans4Less.com, Inc. (LFLS) is an online mortgage broker which matches qualified individuals seeking mortgage loans with suitable lenders who offer the company a competitive wholesale lending program. Maintaining an A+ TrustLink rating with the Better Business Bureau, the company provides competitive rates, terms, costs, daily updates, extensive market information, and trusted first-class service to the public.
Leveraging its portfolio of 62 different web domains, Loans4Less.com is focused on developing a national consumer platform for conforming residential mortgage programs and implementation of other consumer loan programs via operating providers. The company's expansion strategy includes rapidly growing revenues through strategic and cost-effective advertising, licensing, and/or third party agreements that build national recognition of the Loans4Less® brand.
The management team has accumulated many years of experience in the real estate and financial services sectors. This combination of expertise provides the knowledge and foresight necessary to get the best results for the company and their thousands of loyal clients. The team skillfully navigated through the credit crisis that destroyed much of their competition, putting the company in a stronger position to increase market share.
Loans4Less.com is not exposed to the risks and/or problems that are associated with sub-prime lending. Having never defaulting on an obligation or been involved in any litigation, the company is poised for rapid growth in today's low interest rate environment with its industry leading reputation and well established relationships with respected lenders. Disclaimer
Loans4Less.com, Inc. Company Blog
Loans4Less.com, Inc. News:
Loans4Less.com Provides Preliminary Financial Results for the Third Quarter of 2012
Loans4Less.com, Inc. New Audio Interview With Chairman and CEO Steven M. Hershman
Loans4Less.com, Inc. Announces Engagement of QualityStocks Investor Relations Services.
Skinny Nutritional Corp. (SKNY)
The QualityStocks Daily Newsletter would like to spotlight Skinny Nutritional Corp. (SKNY). Today, Skinny Nutritional Corp. closed trading at $0.0018, on 857,250 volume with 15 trades. The stock’s average daily volume over the past 60 days is 1,241,944, and its 52-week low/high is $0.0017/$0.035.
Skinny Nutritional Corp. (SKNY) has established their Skinny Water® brand as a clear alternative to other products in the enhanced water space, with the only true zero calorie, sugar, carb, sodium, and preservative-containing beverage available. Skinny Water's proprietary formulation of essential antioxidant agents, electrolytes, and the critical vitamins our bodies need in order to achieve optimal function, uses 100% natural flavors, no preservatives, no artificial colors, and only the best purified water.
The company has constructed a network of approximately 50 domestic distributors (with three more internationally), placing product on shelves approximately 15k stores across the United States. Derived from the natural flavors contained in fruits, Skinny Water represents a fortified, extremely low-impact, great-tasting array of beverages that provide a concentrated punch of the nutrients essential for a healthier lifestyle.
The company's strong emphasis on health, fitness, and community has served marketing initiatives very well. The new age beverage segment has seen increasing momentum in recent years, with just about every beverage company getting into the game, but none of them has the kind of no-nonsense product composition behind Skinny Water, something that appeals directly to the majority of the core consumer market.
Skinny Nutritional continues to build value around the Skinny Water brand, and today has numerous trademarks in the healthy beverage and snack food categories. As consumers migrate away from sugar based beverages and empty calories, Skinny Water is ideally positioned to benefit from positive market trends as management focuses on delivering exceptional value to shareholders. Disclaimer
Skinny Nutritional Corp. Blog
Skinny Nutritional Corp. News:
Skinny Nutritional Corp. Provides Update on Discussions With Trim Capital
Skinny Nutritional Corp. to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
A&P's 275 Stores Continue Skinny Water's Mid-Atlantic Penetration
A reputation takes a long time to build, but carries more behind-the-scenes influence than anything else. In this world of high-speed global communications and social networking, reputation is very quick to carry. Word gets around about good service and bad service, and the anonymity of the web encourages users to speak their minds, even to the point of exaggeration. In addition, if your interface with the public is primarily online, the importance of reputation is even greater, since the consumer isn’t able to look anyone in the eye and develop a personal relationship. With all of the talk about facilitating communication, the web has more often been called cold and impersonal, making it difficult for industries that used to depend upon trust and a handshake.
Loans4Less, a web-based mortgage broker, focused largely on the California residential marketplace, has recognized this critical fact from the beginning, to the point that the company has based its entire philosophy on transparency and up-front reliable data, with none of the hidden fees and other ugly surprises that consumers have come to expect from much of the mortgage industry. Although they are quick to display their hard-earned official credentials, such as an A+ TrustLink Rating from the Better Business Bureau and an Internet Consumer Group award for being in the top 10% nationally for consumer satisfaction, their real strength is the undercurrent of positive response from users. It’s this informal word that carries the weight.
The company’s website, in addition to a comprehensive range of straight-forward data on interest rates, points, and market conditions, also links to a full-page company commitment statement, stating very clearly that they do not quote rates and/or points that are not deliverable. They do not practice inducement tactics such as posting unrealistic quotes. Nor do they sell or pass on a prospect’s confidential information to any third party and do not order a credit profile reports without a prospect’s prior permission.
In short, the company knows what’s really important to online consumers, and has made it a foundational part of their strategic growth plan.
For more information, visit www.Loans4Less.com
A recent article by Mandy Oaklander in Health on Today, entitled “Diet soda is doing these 7 awful things to your body,” came down on the often hidden risks of drinking diet soda in a way that will open a lot of people’s eyes. When improved artificial sweeteners began to come out a few decades ago, it was seen as a boon to soda drinkers everywhere. At last people could enjoy their favorite sweetened beverages without worrying about sugar and weight gain. But this is not how it turned out.
First of all, as the article points out, Americans drink a lot of pop, approximately 2 cans of the stuff each and every day. Children especially are gulping down diet soda at an increasing rate. But a range of serious problems are now beginning to show up that should give pause to anyone ready pick up that can.
The article indicates, for example, how an 11-year Harvard Medical School study of over 3,000 women found that diet cola is linked to a doubling of risk for kidney decline. It was a decline not associated with sugar-sweetened sodas. The article also pointed to a University of Minnesota study of nearly 10,000 adults suggesting that even one diet soda a day may be associated with a significantly increased risk of metabolic syndrome, including belly fat and high cholesterol, although other factors may have also been involved. In addition, a University of Texas study found that, the more diet sodas a person drinks, the greater the likelihood that they will go on to become overweight. It is suspected that artificial sweeteners disrupt the body’s natural ability to regulate calorie intake, encouraging users to overeat.
When added to a number of other negative aspects of diet soda, including associated chemicals that may cause cell damage, plus rotting teeth, and even reproductive issues, the risks of diet soda become far greater than any perceived benefits.
The spread of this news over the web can’t help but support Skinny Nutritional, producers of Skinny Water, a naturally sweetened water beverage with zero calories and zero carbs, and could explain the rapid expansion of the product’s sales across the country.
For additional information, visit www.SkinnyWater.com
Domestic and international logistics services company Radiant Logistics announced it has completed the acquisition of the assets of its operating partner Marvir Logistics, a privately held Los Angeles-based company that has operated under Radiant Logistics’ Airgroup brand since 2006. Similar to its previous acquisitions, Radiant structured the transaction with a portion of the expected purchase price payable in subsequent periods based on the future performance of the acquired operation.
On a post-closing basis, Marvir will continue its operations under the Airgroup brand for the remainder of 2012, and it is expected that Marvir will transition to the Radiant brand early next year as it is combined with existing company-owned operations in Los Angeles. The combination is additionally expected to provide meaningful cost synergies relating to the elimination of redundant facilities.
Continuing his role as regional director, Michael St. Julien will take the helm of operations for the newly combined organization, which is anticipated to generate around $15 million in annual revenue. Continuing in a leadership role as vice president of sales, Walter Benvenuto will manage the newly combined organization’s sales team. After 40 years of service in the transportation industry, Tom Bowling will transition into retirement.
When Marvir aligned with Radiant in September 2006, the entrepreneurs behind the company found a partner that provided an environment allowing them to build their business, share in the value creation opportunity as shareholders, and transition their business in a way that met their own personal goals and took into consideration the interests of their customers and employees. Marvir was the first new station to join the Radiant family, and from the beginning they participated as shareholders and as one of the larger operating partners in the Radiant network.
Radiant’s founders launched the company in January 2006. Their aim was to bring value to logistics entrepreneurs, like the founders of Marvir, who could benefit from Radiant’s unique value proposition with the immediate opportunity to become shareholders and share in the value they were helping to create, as well as the longer-term opportunity of utilizing the built-in exit strategy available to entrepreneurs participating in the Radiant network.
The Marvir transaction is indicative of the broader opportunity available to Radiant in the marketplace and the probability that more entrepreneurs – both internal and external to Radiant’s existing network – will look to join the company’s ranks. Radiant’s value proposition continues to gain traction within the forwarding community, and the company remains confident that its growth strategy will continue bringing value to its operating partners, shareholders and end customers.
Radiant Logistics is a non-asset-based transportation and logistics company providing domestic and international freight forwarding and fulfillment services through a network of company-owned and exclusive agent offices throughout North America. Radiant operates under the Radiant, Airgroup, Adcom, and DBA brands, servicing a varied account base that includes manufacturers, distributors, and retailers through its network of independent carriers and international agents strategically positioned across the globe.
For more information, visit the company’s website at www.RadiantDelivers.com
PositiveID Corp., an emerging growth company and developer of airborne bio-threat detection systems for America’s homeland defense industry as well as advanced technologies for diabetes management and rapid medical testing, provided a third quarter 2012 business update to its stockholders. The Company continues to focus on the BioWatch Generation 3, Phase II procurement. In September, the Department of Homeland Security (“DHS”) announced a revised procurement strategy for BioWatch Generation 3, Phase II, which will consist of a two-stage procurement including two to three years of testing estimated at $89 million. A draft request for proposal (“RFP”) for the first stage is scheduled to be released in the fourth quarter of calendar 2012.
William J. Caragol, Chairman and CEO of PositiveID, stated, “To position the Company for the first stage of the revised procurement strategy for BioWatch Generation 3, Phase II, we are actively involved in discussions with several potential strategic partners, including both manufacturing partners and systems integration partners. We are focused on trying to bring those discussions to a strategic agreement during the fourth quarter. We also plan in the coming weeks to update stockholders on the progress of our second half of 2012 goals, which we announced in our mid-year update.”
With its acquisition of Microfluidic Systems in May 2011, PositiveID added airborne pathogen detection, rapid clinical diagnostics and sample preparation applications to its business. PositiveID’s M-BAND (Microfluidics-based Bioagent Networked Detector) is a bioaerosol monitor with fully integrated systems with sample collection, processing and detection modules that continuously analyze air samples for the detection of bacteria, viruses, and toxins with results in as little as two hours. M-BAND was developed under a competitive award from the DHS Science & Technology Directorate (“S&T”) and was the only system of its kind demonstrated previously in the field under the DHS S&T BAND Program.
The total procurement for BioWatch Generation 3, Phase II, is estimated at $3.1 billion. The goal of BioWatch Generation 3, Phase II is to obtain a fully autonomous networked biodetection capability that will be deployed, operated, and sustained, both indoor and outdoor, in selected U.S. BioWatch jurisdictions to continuously monitor the air for agents of biological concern. The revised strategy for BioWatch Generation 3, Phase II, will consist of a two-stage procurement. Stage 1 will be for Performance Testing of candidate systems and may result in the award of multiple contracts depending on the technical merits of proposals submitted and the availability of funding. Stage 2 will be a separate competition for Low Rate Initial Production, Operational Testing and Evaluation, Full Rate Production, Deployment, Sustainment and Disposal. To be considered for the Stage 2 award, a company will need to demonstrate a design maturity and data set equivalent to that of Stage 1 participants.
Today's Top 3
The Stock Psycho
OTC Stock Pick
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Cardium Therapeutics, Inc. (CXM) Announces the Acquisition of To Go Brands
- Consorteum Holdings, Inc. (CSRH) Subsidiary, Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming with the Acquisition of To Go Brands
- GlobalWise Investments, Inc. (GWIV) Announces New Channel Partnership With Level Seven
- GreeneStone Healthcare Corp. (GRST) Implementing 'Build & Buy' Growth Strategy To Capitalize On Huge Opportunity In Behavioral Treatment
- International Stem Cell Corp. (ISCO) Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine
- Loans4Less.com, Inc. (LFLS) New Audio Interview With Mr. Steven M. Hershman, Chairman and CEO via SmallCapVoice
- Skinny Nutritional Corp. (SKNY) to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
- Teletouch Communications, Inc. (TLLE) Returns as Official Cellular Sponsor for the 10th Anniversary ESPN 2012 Bell Helicopter Armed Forces Bowl
- TNI BioTech Inc. (TNIB) Dr. Henry "Skip" Lenz, Pharm.D, Joins the Company as Quality Control Officer
- VistaGen Therapeutics, Inc. (VSTA) Announces Strategic Financing With Platinum Long Term Growth Fund